In the hereby presented proof-of-concept study, targeted phagocytosis for cancer immunotherapy was substituted by targeting MerTK on macrophages and the epidermal growth factor receptor (EGFR) that is overexpressed on a plethora of tumour types [33,34,35]. Here, EGFR is linked to neoplasm.